The National Highway Traffic Safety Administration (NHTSA) said that Ford Motor (F) has recalled 38,714 units of Mustang Mach-E SUV in North America and Europe for improperly attached windshields and sunroofs, according to a report published by Detroit Free Press.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Documents that the company filed with the U.S. Department of Transportation stated that all the recalled vehicles were manufactured between February 24, 2020, and July 18, 2021, and may not be properly bonded during the manufacturing process.
There can be increased wind noise or water leaks, or both, in the defective vehicles, which can lead to the detachment of windshields and sunroofs, creating a risk of crash or injury, the NHTSA said.
Ford said, “All of the vehicles have improperly attached windshields, while 27,318 of them also may have faulty panoramic glass roof adhesion.”
The recall includes 13,544 vehicles for roof glass repair and 17,692 vehicles for windshield repair only in the U.S. There have not been any reports of accidents or injuries related to these problems, according to the regulatory documents.
Notably, all Mach-E vehicles sold across the globe are built at a plant located in Cuautitlán Izcalli, Mexico. (See Ford stock chart on TipRanks)
On September 10, Wells Fargo (WFC) analyst Colin Langan maintained a Buy rating on the stock with a price target of $17 (23.4% upside potential). The analyst expects the company to report earnings per share (EPS) of $0.14 in the third quarter.
Overall, the stock has a Moderate Buy consensus rating based on 5 Buys and 3 Holds. The average Ford Motor price target of $16.16 implies 17.3% upside potential. Shares have gained nearly 106% over the past year.
According to TipRanks’ Smart Score rating system, Ford scores an 8 out of 10, suggesting that the stock is likely to outperform market averages.
Related News:
Pfizer, Opko’s BLA for Pediatric GHD Treatment Extended
Uber Deepens Partnership with Rite Aid; Street Says Buy
Understanding Dynatronics’ Risk Factors
